title: Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
abstract: We determined the in vitro activity of SMT19969 and 11 comparators, including metronidazole, vancomycin, and fidaxomicin, against 107 C. difficile isolates of different antimicrobial resistance phenotypes. Fidaxomicin and SMT19969 were the most active. The fidaxomicin and SMT19969 geometric mean MICs were highest in ribotypes known to show multiple resistance. Coresistance to linezolid and moxifloxacin was evident in ribotypes 001, 017, 027, and 356. The high-level ceftriaxone resistance in ribotypes 356 and 018 was location linked.
authors.affiliation: Microbiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
authors.forename: Jane
authors.initials: J
authors.lastname: Freeman
authors.affiliation: Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Vernon
authors.affiliation: Summit Therapeutics, Abingdon, Oxfordshire, United Kingdom.
authors.forename: Richard
authors.initials: R
authors.lastname: Vickers
authors.affiliation: Microbiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom mark.wilcox@nhs.net.
authors.forename: Mark H
authors.initials: MH
authors.lastname: Wilcox
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D002443:Ceftriaxone / Q000494:pharmacology; D016360:Clostridioides difficile / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D003015:Clostridium Infections / Q000188:drug therapy / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D000077732:Fidaxomicin; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D010641:Phenotype; D011725:Pyridines / Q000494:pharmacology*; D021521:Ribotyping; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001562:Benzimidazoles; D024841:Fluoroquinolones; D011725:Pyridines; C000601750:ridinilazole; D008795:Metronidazole; D014640:Vancomycin; D002443:Ceftriaxone; D000069349:Linezolid; D000077266:Moxifloxacin; D000077732:Fidaxomicin